News & Events

Date Title and Summary Additional Formats
Toggle Summary Shareholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
CAMBRIDGE, Mass., May 13, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2010 Annual Meeting of Shareholders. At the meeting, shareholders re-elected director nominees Dr. Joshua Boger, Dr. Charles A. Sanders and Elaine S.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Redemption Date for 4.75% Convertible Senior Subordinated Notes due 2013
CAMBRIDGE, Mass., Feb 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on March 19, 2010 it will redeem the outstanding $32.1 million aggregate principal amount of 4.75% Convertible Senior Subordinated Notes due 2013, in accordance with the terms of the
View HTML
Toggle Summary Vertex Reviews 2010 Business Priorities to Support Goal of Becoming Fully-Capable Biopharmaceutical Company
<i>-HCV:</i><i>New Drug Application planned for telaprevir in second half of 2010, robust commercialization and launch preparedness activities ongoing-</i><br /><i>-CF:</i><i>Advancing development efforts in orphan disease of cystic fibrosis; Phase 3 STRIVE trial with VX-770 completes planned enrollment, VX-809 Phase 2 data expected in first quarter 2010-</i><br /><i>-Pipeline:</i><i>Proof-of-concept clinical trials planned for 2010 with novel combination regimens for hepatitis C and cystic fibrosis and with compounds for rheumatoid arthritis and epilepsy-</i><br /><i>-Financial:</i><i>Vertex enters 2010 with approximately $1.3 billion in cash, cash equivalents &amp; marketable securities and approximately $32 million in outstanding convertible debt-</i><br />
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VCH-222 Abstracts for Presentation at EASL Annual Meeting
<i><b>- PROVE 3 SVR results accepted as late-breaker oral presentation -</b></i><i><b>- First clinical results for VCH-222 in HCV patients accepted as poster presentation -</b></i>
View HTML
Toggle Summary New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection
New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection PROVE 3 data show 52% SVR12 in HCV treatment-failure patients with 24-week treatment duration PROVE 2 final results confirm 69% SVR in HCV treatment-naïve patients with 24-week
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass., Sep 22, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriter has exercised in full its option to purchase 1,125,000 shares of common stock at a public offering price of $25.50 per share.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Pricing of its Public Offering of Common Stock
CAMBRIDGE, Mass., Sep 18, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 7,500,000 shares of its common stock in an underwritten offering at a price to the public of $25.50 per share, which would result in
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Sep 17, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 7,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf
View HTML
Toggle Summary Vertex Pharmaceuticals Announces the Appointment of Freda C. Lewis-Hall, M.D., as Executive Vice President, Medicines Development
CAMBRIDGE, Mass., Jun 18, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Freda C. Lewis-Hall, M.D. as Executive Vice President, Medicines Development. Dr. Lewis-Hall joins Vertex from Bristol-Myers Squibb, Incorporated, and has
View HTML
Toggle Summary Vertex Establishes Early-Stage Huntington's Disease Research Collaboration with CHDI Foundation, Inc.
Vertex Establishes Early-Stage Huntington's Disease Research Collaboration with CHDI Foundation, Inc. -Vertex to receive up to $4 million in funding for Huntington's disease research- -Novel venture philanthropy model used in Vertex's Cystic Fibrosis R&amp;D efforts to support new Huntington's disease
View HTML
Toggle Summary Vertex Pharmaceuticals Sells HIV Product Royalty Stream for $160 Million
CAMBRIDGE, Mass., Jun 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has sold its rights to future royalties in Lexiva(R) and Agenerase(R) under its 1993 license agreement with GlaxoSmithKline plc (GSK) in the field of HIV protease inhibitors
View HTML
Toggle Summary Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
CAMBRIDGE, Mass., May 15, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2008 Annual Meeting of Stockholders. At the meeting, stockholders approved the amendment to Vertex's Articles of Organization increasing the number of
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Completion of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes
CAMBRIDGE, Mass., Feb 19, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offerings of 6,900,000 shares of common stock, including 900,000 shares purchased by the underwriters pursuant to their over-allotment option, and $287.5
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Exercise of Over-Allotment Options by Underwriters of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes
Vertex Pharmaceuticals Announces Exercise of Over-Allotment Options by Underwriters of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes CAMBRIDGE, Mass., Feb 13, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Pricing of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes
CAMBRIDGE, Mass., Feb 12, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 6,000,000 shares of its common stock in an underwritten offering at a price to the public of $17.14 per share.
View HTML
Toggle Summary Vertex Pharmaceuticals Reviews 2008 Business Priorities and Reports 2007 Financial Results
-- Focused on first-to-market opportunity with HCV protease<br> inhibitor telaprevir --<br><br> -- Additional drug candidates directed at HCV, cystic fibrosis and<br> immune-mediated diseases--
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes
CAMBRIDGE, Mass., Feb 11, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 6,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update
Vertex Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update Important telaprevir data to be presented at AASLD – Additional compounds for HCV and Cystic Fibrosis scheduled to enter development – Cambridge, MA, October 29, 2007 — Vertex
View HTML
Toggle Summary Vertex Announces Publication of Abstracts for Presentation at 58th AASLD Meeting
-- Conference Presentations to Include Data from Two Randomized, Controlled Phase 2 Clinical Studies of Investigational HCV Protease Inhibitor Telaprevir --
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Second Quarter 2007 Financial Results and Provides Development Pipeline Update
CAMBRIDGE, Mass., Jul 24, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2007, and the Company provided a pipeline update. "Vertex achieved its major development pipeline milestones in the first
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Two Executive Appointments
CAMBRIDGE, Mass., Jun 29, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Kurt C. Graves as Executive Vice President, Chief Commercial Officer and Head, Strategic Development. Vertex also announced today that Amit K.
View HTML
Toggle Summary Stockholders of Vertex Pharmaceuticals Re-elect Directors at Annual Meeting
CAMBRIDGE, Mass., May 31, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2007 Annual Meeting of Stockholders. At the meeting, stockholders re-elected Joshua Boger, Ph.D., Charles A. Sanders, M.D., and Elaine S.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Completion of Conversion of Outstanding 5.75% Convertible Senior Subordinated Notes due 2011
CAMBRIDGE, Mass., Mar 05, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that in connection with the previously announced redemption of its 5.75% Convertible Senior Subordinated Notes due 2011, holders of all of the outstanding notes converted their notes
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Redemption Date for 5.75% Convertible Senior Subordinated Notes due 2011
Vertex Pharmaceuticals Announces Redemption Date for 5.75% Convertible Senior Subordinated Notes due 2011 Cambridge, MA, February 2, 2007 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on March 5, 2007 it will redeem the outstanding $59.6 million aggregate principal amount of
View HTML
Toggle Summary Vertex Pharmaceuticals Reports 2006 Financial Results
Vertex Pharmaceuticals Reports 2006 Financial Results Cambridge, MA, February 1, 2007 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter and year ended December 31, 2006. “2006 was characterized by significant progress across our
View HTML
Toggle Summary Vertex Pharmaceuticals Added to NASDAQ-100 Index
Vertex Pharmaceuticals Added to NASDAQ-100 Index Cambridge, MA, December 11, 2006 -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Company will be added to the NASDAQ-100 Index(R), effective with the market open on Monday, December 18, 2006.
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Third Quarter 2006 Financial Results
- Company Reiterates Anticipated Timeline of Clinical Milestones -
View HTML
Toggle Summary Vertex Pharmaceuticals and GlaxoSmithKline Announce Virologic and Drug Resistance Results from Protease Inhibitor Study
Vertex Pharmaceuticals and GlaxoSmithKline Announce Virologic and Drug Resistance Results from Protease Inhibitor Study San Francisco, CA, September 28, 2006 -- Data presented today show low rates of virologic failure and antiviral drug resistance with the HIV protease inhibitor LEXIVA boosted with
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Completion of Common Stock Offering
Vertex Pharmaceuticals Announces Completion of Common Stock Offering Cambridge, MA, September 20, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common stock. The gross proceeds, before commissions and
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Pricing of Common Stock Offering
Vertex Pharmaceuticals Announces Pricing of Common Stock Offering Cambridge, MA, September 14, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common stock at a price of $33.00 per share.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock
Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock Cambridge, MA, September 11, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to offer 8,000,000 shares of its newly issued common stock in an underwritten public offering.
View HTML
Toggle Summary Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet
LEXIVA(R)/r Twice-Daily Provided Comparable Efficacy to Kaletra Twice-Daily in Treatment-Naive HIV Patients
View HTML
Toggle Summary Updated HIV Treatment Guidelines Now Include LEXIVA(R) (fosamprenavir calcium)/r for Initial Antiretroviral Treatment Regimens
Updated HIV Treatment Guidelines Now Include LEXIVA(R) (fosamprenavir calcium)/r for Initial Antiretroviral Treatment Regimens Toronto, Canada, August 13, 2006 -- Updated treatment guidelines issued today by the International AIDS Society-USA (IAS-USA) now include the HIV protease inhibitor
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011
Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011 Cambridge, MA, August 3, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that three holders of its 5.75% Convertible Senior
View HTML
Toggle Summary Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV
Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson &amp; Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV CAMBRIDGE, Mass. and NEW BRUNSWICK, N.J., June 30 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals
View HTML
Toggle Summary GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV
GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV Research Triangle Park, NC, and Cambridge, MA, May 16, 2006 -- GlaxoSmithKline (GSK) and
View HTML
Toggle Summary Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
- Company Updates Corporate Governance Practices -
View HTML
Toggle Summary Vertex Pharmaceuticals Reports First Quarter 2006 Financial Results
&#150;&#150; Company on Track to Achieve Clinical, Research and Corporate Objectives &#150;&#150;
View HTML
Toggle Summary Vertex Pharmaceuticals Reports 2005 Financial Results
- Clinical, Research and Financial Objectives Achieved -
View HTML
Toggle Summary Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research
Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research Cambridge, MA and Bethesda, MD, January 12, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Cystic Fibrosis Foundation Therapeutics, Inc.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference
-Product Candidates with Transformational Potential Highlighted-
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference
&#8212;Product Candidates with Transformational Potential Highlighted&#8212;
View HTML
Toggle Summary VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon
--Median 5.5 log10 reduction in HCV RNA achieved in patients receiving VX-950 and peg-IFN in 14-day clinical study--
View HTML
Toggle Summary GSK and Vertex Pharmaceuticals Announce Presentation of Data Supporting Development of Investigational HIV Protease Inhibitor Brecanavir
- Positive Data Presented at 45th Annual ICAAC -
View HTML
Toggle Summary GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain
- VX-409 is first in a new class of subtype selective ion channel modulators -
View HTML
Toggle Summary GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain
- VX-409 is first in a new class of subtype selective ion channel modulators -
View HTML
Toggle Summary FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
FDA Grants Fast Track Designation to Vertex’s Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to
View HTML
Toggle Summary Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study
- Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors -
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
- Investigational New Drug Application Activated in the U.S. -
View HTML
Toggle Summary FDA Approves Updated Labeling for LEXIVA
- Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA -
View HTML